Lexicon Pharmaceuticals, Inc.

LXRX05 Dec 2024
Healthcare
$0.71
-0.04 (-3.89%)
Lowest Today
$0.68
Highest Today
$0.72
Today’s Open
$0.71
Prev. Close
$0.71
52 Week High
$3.73
52 Week Low
$0.68
To Invest in Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.

Healthcare
LXRX05 Dec 2024
-0.04 (-3.89%)
1M
3M
6M
1Y
5Y
Low
$0.68
Day’s Range
High
$0.72
0.68
52 Week Low
$0.68
52-Week Range
52 Week High
$3.73
0.68
1 Day
-
1 Week
-14.62%
1 month return
-42.37%
3 month return
-57.71%
6 month return
-64.61%
1 Year return
-40.09%
3 Years return
-83.5%
5 Years return
-83.95%
10 Years return
-
Institutional Holdings
Artal Group S A
37.67
FMR Inc
13.79
Fidelity Growth Compy Commingled Pl S
6.12
Fidelity Growth Company Fund
4.35
Orbimed Advisors, LLC
3.05
BlackRock Inc
2.74
Vanguard Group Inc
2.24

Market Status

Fundamentals
Market Cap
257.71 mln
PB Ratio
1.44
PE Ratio
0
Enterprise Value
132.35 mln
Total Assets
229.43 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Organisation
Lexicon Pharmaceuticals, Inc.
Employees
285
Industry
Biotechnology
CEO
Dr. Michael  Exton Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities